Priliximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD4 |
| Clinical data | |
| Identifiers | |
147191-91-1  | |
| None | |
| Chemical data | |
| (what is this?) (verify) | |
Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease[1] and multiple sclerosis[2][3] but has not yet received U.S. Food and Drug Administration licencing. The patent belongs to the biotechnology company Centocor.
References
- ↑ Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S (1997). "CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study". Gut 40 (3): 320–7. doi:10.1136/gut.40.3.320. PMC 1027080. PMID 9135519.
- ↑ Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M (1997). "Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412". Neurology 48 (4): 810–6. doi:10.1212/wnl.48.4.810. PMID 9109860.
- ↑ van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr H.J., Polman C (1997). "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial". Neurology 49 (2): 351–7. doi:10.1212/wnl.49.2.351. PMID 9270561.